Evidence map›Paper›PMID 40836488›Full record

ArticleJournal of the International AIDS Society2025

Preferences for HIV pre-exposure prophylaxis among men who have sex with men and trans women in 15 countries and territories in Asia and Australia: a discrete choice experiment.

Warittha Tieosapjaroen, Benjamin R Bavinton, Heather-Marie A Schmidt, Curtis Chan, Kim E Green, Nittaya Phanuphak, Midnight Poonkasetwattana, Nicky S Suwandi, Doug Fraser, Hua Boonyapisomparn and 4 more

Abstract read
In one paragraph

Article in Journal of the International AIDS Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Warittha TieosapjaroenThe School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0001-9712-9262
Benjamin R BavintonKirby Institute, University of New South Wales, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0001-5834-8278
Heather-Marie A SchmidtUNAIDS Regional Office for Asia and the Pacific, Bangkok, Thailand.ORCID https://orcid.org/0000-0002-2629-6407
Curtis ChanKirby Institute, University of New South Wales, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-9581-1011
Kim E GreenThe Program for Appropriate Technology in Health, Hanoi, Vietnam.
Nittaya PhanuphakInstitute of HIV Research and Innovation, Bangkok, Thailand.ORCID https://orcid.org/0000-0002-0036-3165
Midnight PoonkasetwattanaAsia Pacific Coalition on Male Sexual Health, Bangkok, Thailand.
Nicky S SuwandiAsian Pacific Transgender Network, Bangkok, Thailand.
Doug FraserKirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
Hua BoonyapisomparnAsian Pacific Transgender Network, Bangkok, Thailand.
Michael CassellFamily Health International 360, Hanoi, Vietnam.
Lei ZhangThe School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.
Weiming TangThe University of North Carolina at Chapel Hill Project-China, Guangzhou, China.ORCID https://orcid.org/0000-0002-9026-707X
Jason J OngThe School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.

Funding

MAC AIDSNSW Ministry of HealthThe Australian Government Department of HealthViiV HealthcareWorld Health Organization 001
6 · The paper itself

Abstract

introductionScaling up pre-exposure prophylaxis (PrEP) for HIV among men who have sex with men (MSM) and transgender women (TGW) in the Asia-Pacific region has been slow. We identified the drivers of PrEP use and forecasted PrEP uptake given different PrEP programmes for MSM and TGW living in 15 countries and territories in Asia and Australia.

methodsSeparate online discrete choice experiment surveys for MSM and TGW were distributed in 15 Asian countries and territories and Australia between May and November 2022. We used random parameters logit models to estimate the relative importance of service attributes and predicted PrEP uptake for different programme configurations.

resultsAmong 21,943 participants included in the MSM survey and 1522 in the TGW survey, the mean age was 31.7 (±9.5) years and 28.1 (±7.0) years, respectively. Cost emerged as the primary driver of PrEP use for MSM and TGW across countries, followed by the type of PrEP. When switching from the least preferred PrEP programme (i.e. very high service fee, PrEP implant, rare kidney problems as side effects of PrEP and a 2-monthly clinic visit) to an optimal programme (i.e. free access to PrEP via peer-led community clinics which offered sexually transmitted infection [STI] testing, and a 6-12 monthly visit), the predicted PrEP uptake could improve by over 50% for MSM in Australia, China, Hong Kong SAR China, Japan, the Philippines, Taiwan (China) and Thailand, and 37% for TGW. Compared to those at lower risk of HIV, free access was more preferred by MSM at a higher risk of HIV, while telehealth was more preferred by TGW at a substantial risk of HIV.

conclusionsTailoring services to local contexts, including ensuring affordability, preferred type of PrEP and providing differentiated services, could accelerate the uptake of PrEP among MSM and TGW in Asia and Australia. Novel innovations, such as STI and HIV self-testing, should be explored as alternatives to conventional testing, given that most MSM and TGW prefer less frequent clinic visits and long-acting PrEP options.

Indexed as

Anti-HIV AgentsHIV InfectionsHomosexuality, MalePatient PreferencePre-Exposure ProphylaxisTransgender PersonsAdultAsiaAustraliaFemaleHumansMaleMiddle AgedSexual and Gender MinoritiesSurveys and QuestionnairesYoung AdultAnti-HIV AgentsHIV acquisitionsHIV preventionmen who have sex with menpre‐exposure prophylaxissexual and gender minoritiestransgender persons

Identifiers

PMID40836488
PMCPMC12367860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.